miRagen Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies. The company is focused on clinical testing of VRDN-001, an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) in development for thyroid eye disease (TED), and a pipeline of novel therapies for TED and X-linked hypophosphatemia (XLH), a rare genetic disease causing osteomalacia resulting in bone deformity, impaired growth and fractures. miRagen is headquartered in Boulder, CO, with R&D operations based in Waltham, Mass.